NCT00478504

Letrozole Versus Clomifene Citrate for Ovulation Induction

Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 159 (actual)
• Sponsor: University of Nottingham · Academic / Other
• Sex: Female
• Age: 18 Years – 39 Years
• Healthy volunteers: Not accepted

Summary

The primary aim of the study is to assess the efficacy of letrozole as an ovulation induction agent and to test the hypothesis that letrozole will generate better pregnancy rates with fewer multiple pregnancies and higher live birth rate than the current standard agent, clomifene citrate in anovular infertile women with polycystic ovarian syndrome.

Conditions

• Infertility
• Polycystic Ovarian Syndrome

Interventions

Type	Name	Description
DRUG	Letrozole	Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
DRUG	Clomifene citrate	Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg

Timeline

• Start date: 2007-05-01
• Primary completion: 2014-06-01
• Completion: 2014-09-01
• First posted: 2007-05-24
• Last updated: 2016-10-28

Locations

1 site across 1 country: United Kingdom